New GLP-1 Weight-Loss Drugs Expected This Year
This Medical News article discusses clinical trial data for weight-loss medications, in both injectable and pill formations, that are currently under review with US Food and Drug Administration.
Bariatric Surgery and GLP-1 Drugs Both Support Sustained Fat Loss
Although bariatric surgery was associated with more evident changes, research found that treatment with glucagon-like peptide-1 (GLP-1) medications was also associated with sustained fat loss in a clinical setting.
FDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA Medications
The US Food and Drug Administration (FDA) requested that drug application holders remove suicidal ideation and behavior warnings from glucagon-like peptide-1 (GLP-1) receptor agonists.
CHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshild
EU regulators have refused to greenlight Eli Lilly’s weight loss drug Mounjaro as a treatment for a type of heart failure, while giving the go-ahead for Novo Nordisk’s semaglutide in liver disease.
Lilly failed to …
IJMS, Vol. 27, Pages 1409: Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes
IJMS, Vol. 27, Pages 1409: Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes International Journal of Molecular Sciences doi: 10.3390/ijms27031409 Authors: Urna Kansakar Stanislovas S. Jankauskas Shivangi Pande Pasquale Mone Fahimeh Varzideh Gaetano Santulli Orforglipron (LY3502970) is a novel, orally available, nonpeptide glucagon-like peptide-1 receptor agonist […]
Regeneron (REGN) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool. Date Jan. 30, 2026, 8:30 a.m. ET Call participants President and Chief Executive Officer — Dr. Leonard Schleifer Board Co-Chair, President, and Chief Scientific Officer — Dr. George Yancopoulos Executive Vice President, Commercial — Marion McCourt Executive Vice President and Chief Financial Officer — Christopher Fenimore Vice President, Investor Relations […]
GLP-1 Warning Over Link to Fatal Events; DOJ Sues Med School; Genes and Longevity
(MedPage Today) — Note that some links may require registration or subscription. The United Kingdom’s Medicines and Healthcare Products Regulatory Agency strengthened its warnings on GLP-1 receptor agonists and dual GLP-1/GIP agonists to include…
Heart Failure Data Added to GLP-1 Prescribing Info
Mounjaro significantly reduced hospitalizations in adults with obesity and symptomatic chronic heart failure with preserved ejection fraction. Medscape News Europe
Roche Holding AG (OTC:RHHBY) Q4 2025 Earnings Call Transcript
Roche Holding AG (OTC:RHHBY) Q4 2025 Earnings Call Transcript January 29, 2026 Roche Holding AG beats earnings expectations. Reported EPS is $1.36, expectations were $1.35. Operator: Ladies and gentlemen, welcome to Roche’s Full Year Results Webinar 2025. My name is [ Henrik, ] and I’m the technical operator for today’s call. Kindly note that the […]
GLP-1 Weight Loss Drugs and the ‘Exploding Colon’ Lawsuits: A Symptom of a Deeper Health Crisis
(NaturalNews) IntroductionA seismic shift in American health culture is being violently undone in courtrooms across the nation. The blockbuster GLP-1 weight-loss …